|
Report Date : |
06.04.2014 |
IDENTIFICATION DETAILS
|
Name : |
MS KOREA CO., LTD. |
|
|
|
|
Registered Office : |
10-15, Doanbuk-ro 93beon-gil, Seo-gu,
Daejeon, Korea 300-812 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
05.07.1998 |
|
|
|
|
Com. Reg. No.: |
314-81-21771 |
|
|
|
|
Legal Form : |
Co., Ltd by shares |
|
|
|
|
Line of Business : |
Wholesales of Medical,
Precision and Scientific Instruments and Equipment |
|
|
|
|
No. of Employees |
7 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – december 01, 2013
|
Country Name |
Previous Rating (30.09.2013) |
Current Rating (01.12.2013) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA - ECONOMIC OVERVIEW
South Korea over the past four decades has demonstrated
incredible growth and global integration to become a high-tech industrialized
economy. In the 1960s, GDP per capita was comparable with levels in the poorer
countries of Africa and Asia. In 2004, South Korea joined the trillion dollar
club of world economies, and is currently the world's 12th largest economy.
Initially, a system of close government and business ties, including directed
credit and import restrictions, made this success possible. The government
promoted the import of raw materials and technology at the expense of consumer
goods, and encouraged savings and investment over consumption. The Asian
financial crisis of 1997-98 exposed longstanding weaknesses in South Korea's
development model including high debt/equity ratios and massive short-term
foreign borrowing. GDP plunged by 6.9% in 1998, and then recovered by 9% in
1999-2000. Korea adopted numerous economic reforms following the crisis,
including greater openness to foreign investment and imports. Growth moderated
to about 4% annually between 2003 and 2007. Korea's export focused economy was
hit hard by the 2008 global economic downturn, but quickly rebounded in
subsequent years, reaching 6.3% growth in 2010. The US-South Korea Free Trade
Agreement was ratified by both governments in 2011 and went into effect in
March 2012. Throughout 2012 and 2013 the economy experienced sluggish growth
because of market slowdowns in the United States, China, and the Eurozone. The
administration in 2014 is likely to face the challenge of balancing heavy
reliance on exports with developing domestic-oriented sectors, such as
services. The South Korean economy's long term challenges include a rapidly
aging population, inflexible labor market, and heavy reliance on exports -
which comprise about half of GDP.
|
Source
: CIA |
Basic
|
Company Name |
MS KOREA CO., LTD. |
|
Registered Address |
10-15, Doanbuk-ro 93beon-gil, Seo-gu,
Daejeon, Korea |
|
Zip Code |
300-812 |
|
Tel |
+82-42-635-8333 |
|
Fax |
+82-42-635-8335 |
|
E-mail |
mscorea@mscorea.com;hnkms@chol.com |
|
Website |
www.mscorea.com |
|
Trading Address |
10-15, Doanbuk-ro 93beon-gil, Seo-gu,
Daejeon, Korea (Old Address System : 871, Doan-dong, Seo-gu, Daejeon, Korea) |
|
Tel |
+82-42-635-8333 |
|
Fax |
+82-42-635-8335 |
|
Other Address |
2FL., 174-20, Garak-dong, Songpa-gu, Seoul, Korea |
|
Type |
Import |
|
Industry |
Wholesales of Medical,
Precision and Scientific Instruments and Equipment |
|
Main Business |
Medical Diagnostic Devices, Hematology
& Chemistry Analyzer, Reagent |
|
Established (mm/dd/yyyy) |
05/07/1998 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Laboratory centrifuges and accessories(41103900) |
|
Sell |
Chemical evaluation instruments and supplies(41113000) |
|
Sell |
Clinical and diagnostic analyzer reagents(41116000) |
|
Name |
Han Young-Dong |
|
Address |
Suite 108-406, 70, Mokdong-ro, Jung-gu,
Daejeon, Korea |
|
Date of Birth |
10/20/1951 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
200,000,000 |
|
Employees |
7 |
|
Formation |
Co., Ltd by shares |
|
Bank Details |
Kookmin Bank Woori Bank-Jungchon Dong Branch |
|
Corporate Registered No. |
160111-0071128 |
|
Business Registered No. |
314-81-21771 |
|
Permit & Licenses |
Int’l Trade No.: 16012721 |
|
Shareholder Position |
N/A |
|
Company History |
05/07/1998 Incorporated as the present name 03/25/2010 Increased capital to 200,000,000
KRW from 50,000,000 KRW 03/19/2014 Moved to the present HQ address
from 293-11, Samseong-dong, Dong-gu, Daejeon, Korea |
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Han Young-Dong |
Male |
Korean |
03/31/2004 |
|
Director |
Mr. |
Han Keum-Hyun |
Male |
Korean |
03/31/2004 |
|
Director |
Mr. |
Cho Sung-Hae |
Male |
Korean |
03/31/2004 |
|
Auditor |
M/S. |
Jeong Nam-Su |
Female |
Korean |
03/19/2010 |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
2013 |
|
|
|
|
2012 |
2,757,000,000 |
2,508,000,000 |
62,000,000 |
|
2011 |
3,353,000,000 |
2,352,000,000 |
73,000,000 |
|
2010 |
3,027,000,000 |
2,123,000,000 |
104,000,000 |
|
2009 |
2,493,000,000 |
|
87,000,000 |
|
2008 |
|
|
|
|
2007 |
2,050,000,000 |
1,636,000,000 |
154,000,000 |
|
2006 |
1,822,000,000 |
1,404,000,000 |
156,000,000 |
|
2005 |
1,885,000,000 |
1,265,000,000 |
189,000,000 |
The latest & full financials are not available,
and the Subject Company does not have any obligations to release its financials
to the public.
|
Authorized Capital(KRW) |
200,000,000 |
|
Paid-Up Capital(KRW) |
200,000,000 |
|
Total Issued Shares |
40,000 |
|
Balance Sheet |
|||
|
Unit : Korean Won |
As of 12/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Total Assets |
2,508,000,000 |
2,352,000,000 |
2,123,000,000 |
|
Current Assets |
2,255,000,000 |
2,143,000,000 |
1,956,000,000 |
|
-Quick Assets |
- |
- |
- |
|
-Inventories |
- |
- |
- |
|
Fixed Assets |
253,000,000 |
209,000,000 |
167,000,000 |
|
-Investment |
- |
- |
- |
|
-Tangibles |
- |
- |
- |
|
-Intangibles |
- |
- |
- |
|
Total Liabilities |
1,026,000,000 |
932,000,000 |
771,000,000 |
|
Current Liabilities |
1,026,000,000 |
932,000,000 |
705,000,000 |
|
Fixed Liabilities |
- |
- |
66,000,000 |
|
Capital Stock |
200,000,000 |
200,000,000 |
200,000,000 |
|
Capital Surplus |
- |
- |
- |
|
Profit Surplus |
- |
- |
- |
|
Capital Adjustment |
- |
- |
- |
|
Total Equity |
1,482,000,000 |
1,420,000,000 |
1,352,000,000 |
|
Liab. & Shareholder’s Equity |
2,508,000,000 |
2,352,000,000 |
2,123,000,000 |
|
Income Statement |
|||
|
Unit : Korean Won |
As of 12/31/2012 |
As of 12/31/2011 |
As of 12/31/2010 |
|
Sales |
2,757,000,000 |
3,353,000,000 |
3,027,000,000 |
|
Cost of Sold Goods |
1,818,000,000 |
1,977,000,000 |
1,916,000,000 |
|
Gross Profit |
939,000,000 |
1,376,000,000 |
1,111,000,000 |
|
Selling & Admin. Expenses |
827,000,000 |
1,261,000,000 |
974,000,000 |
|
Operating Income |
112,000,000 |
115,000,000 |
137,000,000 |
|
Non-Operating Income |
12,000,000 |
2,000,000 |
14,000,000 |
|
Non-Operating Expenses |
53,000,000 |
39,000,000 |
38,000,000 |
|
Income Before Taxes |
71,000,000 |
78,000,000 |
113,000,000 |
|
Income Taxes Expenses |
9,000,000 |
5,000,000 |
9,000,000 |
|
Net Income |
62,000,000 |
73,000,000 |
104,000,000 |
|
Main Products & Services |
Medical Diagnostic Devices, Hematology
& Chemistry Analyzer, Reagent |
|
Detailed Products Spec. |
|
|
Technologies Acquired |
|
|
Suppliers |
J.T. BAKER R&D SYSTEM INC. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS
CO., LTD. MINDRAY BUILDING, KEJI 12TH ROAD SOUTH, HIGH-TECH
INDUSTRIAL PARK, NANSHAN, SHENZHEN, 518057, P. R. CHINA TEL:+86-755-26582888 FAX:+86-755-26582680,
26582500 ERBA DIAGNOSTICS MANNHEIM GMBH MALLAUSTRASSE 69-73 68219 MANNHEIM, GERMANY TEL:+49 621 8799770 FAX: +49 621 8799688 ERBA DIAGNOSTICS MANNHEIM GMBH -ASIA
PACIFIC REGIONAL OFFICE 8 CHANDIVALI STUDIO ROAD, MUMBAI - 400 072,
INDIA TEL:+91 22 40309000 FAX:+91 22 40309677 |
|
Customers |
CM KOREA CO., LTD.(KOREA) MSE CO., LTD.(KOREA) Domestic 700 hospitals, Pharmacies |
|
Competitors |
WOONGBEE MEDITECH INC. RM. 1309, BIZ-DONG, SKN TECHNO PARK, 190-1,
SANGDAEWON 1-DONG, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO, KOREA TEL:+82-31-776-3300 FAX:+82-31-776-3303 SHINYANG CHEMICAL CO., LTD. 700-212, MYEONGNYUN 2-DONG, DONGNAE-GU,
BUSAN, KOREA TEL:+82-51-552-7001 FAX:+82-51-552-7018 KDR BIOTECH CO., LTD. 5TH FL., SEGYEONG BLDG., 506-4, AMSA
2-DONG, GANGDONG-GU, SEOUL, KOREA TEL:+82-2-3427-6000 FAX:+82-2-3426-6140 |
|
Sales/ Unit :Mil KRW |
2013 |
2012 |
2011 |
|
Export |
|
|
|
|
Domestic |
|
|
|
|
Total |
|
|
|
The Subject deals with the companies in
Netherlands, China and India.
Not Available.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.32 |
|
UK Pound |
1 |
Rs.100.04 |
|
Euro |
1 |
Rs.82.65 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.